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Other names: LKB1; PJS (Peutz-Jeghers syndrome); 




10 Exons spanning 23 kb, the 10th exon occurs within 
the 3' untranslated region of the gene. The gene is 
transcribed in telomere to centromere direction. 
Transcription 
The length of this transcript has not been reconciled. 
The curated human Vega transcript is the longest 
transcript reported to date (3,627 bp, Vega external 
transcript). The GeneBank sequence is the same but is 
shorter (3,286 bp) at the 3' end (NM_000455.4). The
exon/intron structures in GeneBank are given for 2  
alternative assemblies (aligned with NT_011255.14 and 
NW_927173.1), of which the NT_0112255.14 is 
consistent with the Vega annotation. Alternative 




433 amino acids, 48.6 kDa; N-term with a nuclear 
localization domain and a putative cytoplasmic 
retention signal, a kinase domain, and a C-terminal 
CAAX box prenylation motif. 
Expression 
Ubiquitous, especially high expression in the testis and 
fetal liver. 
Localisation 
Found in both the nucleus and the cytoplasm. 
Localization is thought to be dependent on interaction 
with proteins such as BRG1, LIP1, STRAD, MO25. 
 
 
Diagram of STK11 protein (not drawn to scale). The kinase domain is depicted by the green box. The second box outlined by the 
dashed lines illustrates the location of the nuclear localization signal (NLS) and the purple box indicates the prenylation motif. This 







A serine/threonine protein kinase, recently classified as 
a part of the Ca2+/ calmodulin kinase group of kinases. 
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STK11 was shown to associate and activate the 
pseudokinase, STRAD, resulting in the reorganization 
of non-polarized cells so they form asymmetrical apic l 
and basal structures. Another mechanism by which this 
may occur is by the interaction of STK11 with the 
PAR1 family of serine/threonine kinases. AMPK is a 
protein kinase cascade that plays an important role in 
regulating energy homeostasis. The first report of an 
upstream regulator came when it was discovered that 
STK11, in complex with STRAD and the scaffolding 
protein MO25, can phosphorylate and activate AMPK. 
Subsequently, it was demonstrated that STK11 can 
phosphorylate the T-loop of 12 other AMPK related 
human kinases. In addition it has been implicated in a
range of processes including, chromatin remodeling, 
cell cycle arrest, ras-induced cell transformation, p53 -
mediated apoptosis and Wnt signaling. 
Homology 
Orthologs found in several species and include:  
Xenopus laevis egg and embryonic kinase 1(XEEK1),  
Caenorhabditis elegans partitioning defective gene 4 
(PAR4),  
Mouse LKB1  
and drosophila LKB1. 
Mutations 
Germinal 
Most mutations identified to date are in the catalytic 
domain of STK11, indicating that kinase activity is 
likely essential for its function as a tumor suppressor. 
Several types of mutations including insertions, 
deletions, nonsense, missense and splice site alterations 
have been identified to date. One family has been 
identified with complete germline deletion of this gene. 
Somatic 
Many of the polyps that develop in Peutz-Jeghers 
syndrome (see below) show loss of heterozygosity and 
sometimes somatic mutations. Somatic mutations rarely 
occur in sporadic tumours, with the exception of 
adenocarcinoma of the lung. The inactivation of the
LKB1 can also occur through promoter 
hypermethylation. 
Implicated in 
Peutz-Jeghers syndrome (PJS) 
Disease 
Autosomal dominant syndrome associated with 
mucocutaneous hyperpigmentation and benign 
intestinal polyps known as hamartomas. The relative 
incidence is estimated to vary from 1/29 000 to 1/120 
000 births. Patients are at an increased risk of 
developing malignancies in epithelial tissues, for 
example it has been estimated that there is a about 84, 
about 213 and about 520 fold increased risk of 
developing colon, gastric and small intestinal cancers 
respectively. PJS patients are also at an increased ri k 
of developing cancers in the breast, lung, ovaries, 
uterus, cervix and testes. 
Hybrid/Mutated Gene 
A majority (60-70%) of Peutz-Jeghers patients show 
germline mutations in STK11. Genetic locus 
heterogeneity may exist for this disease. A small 
percentage of families with no mutations in 
STK11/LKB1 have been identified, however no other 
candidate genes that predispose to Peutz-Jeghers 
syndrome have been identified to date. 
Oncogenesis 
Patients inherit mutations in one allele, and the 
remaining allele is later inactivated generally by LOH 
or sometimes somatic mutation. This biallelic 
inactivation of STK11 leads to a loss of tumour 
suppressor activity, thereby promoting tumourigenesis. 
Lung adenocarcinoma 
Disease 
Adenocarcinoma is the most common non-small-cell 
lung cancer accounting for about 30-40% of all cases 
diagnosed to date. These tumors are thought to derive 
from epithelial cells that line the peripheral small 
airways and the heterogeneity of lung tumours is well
documented. The outcome of non-small cell lung 
cancer is more difficult to predict, and about 50% of 
patients die from metastatic disease even after surgery 
of the primary tumour. 
Hybrid/Mutated Gene 
As many as 33% of sporadic lesions analyzed display 
somatic mutations in STK11. 
Oncogenesis 
Loss of protein function is seen in sporadic lung 
adenocarcinoma tumours. 
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